Comparison of Available Treatments for Tobacco Addiction
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Cigarette smoking is a major public health problem that causes more than 5 million deaths annually worldwide. Cigarette smoking is especially common among individuals with psychiatric comorbidity, including individuals with primary psychiatric disorders and other addictions. Effective behavioral and pharmacologic treatments for smoking cessation are available. Behavioral treatments including brief (< 3 min) counseling by physicians are effective. Seven first-line pharmacologic treatments are currently available: five nicotine replacement therapies, bupropion, and varenicline. In addition, clonidine and nortriptyline are second-line treatments for smoking cessation. These treatments increase the chances of quitting smoking by two- to threefold, supporting their use in smokers who are motivated to quit. However, effective treatments for many subpopulations, including smokers with psychiatric comorbidities as well as adolescent, pregnant, or postpartum smokers, remain to be developed and represent an important challenge.
- Thorne SL, Malarcher A, Maurice E, Caraballo R: Cigarette smoking among adults—United States, 2007. JAMA 2009, 301:373–375. CrossRef
- Grant BF, Hasin DS, Chou SP, et al.: Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004, 61:1107–1115. CrossRef
- •• Fiore MC, Jaén CR, Baker TB, et al.: Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2008. The clinical practice guidelines are the main resource for treating individuals with tobacco use and dependence. The guidelines are based on the review of literature for most evidence-based treatments.
- Le Foll B, Wertheim C, Goldberg SR: High reinforcing efficacy of nicotine in non-human primates. PLoS One 2007, 2:e230. CrossRef
- • Sofuoglu M, Yoo S, Hill KP, Mooney M: Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology 2008, 33:715–720. Although nicotine is the main addictive chemical in tobacco, there have been few studies of pure nicotine self-administration in humans. This study showed that smokers self-administer intravenous nicotine doses that are within the range of those of average intake from cigarette smoking. This model may be useful in the evaluation of the effects of both behavioral and pharmacologic manipulations on nicotine self-administration in humans. CrossRef
- Dani JA, Bertrand D: Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007, 47:699–729. CrossRef
- Balfour DJ: The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol 2009, 192:209–233. CrossRef
- Quick MW, Lester RA: Desensitization of neuronal nicotinic receptors. J Neurobiol 2002, 53:457–478. CrossRef
- Mansvelder HD, Keath JR, McGehee DS: Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 2002, 33:905–919. CrossRef
- Mottillo S, Filion KB, Belisle P, et al.: Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J 2009, 30:718–730. CrossRef
- Clarke PB: Nicotine dependence—mechanisms and therapeutic strategies. Biochem Soc Symp 1993, 59:83–95.
- Physicians’ Desk Reference. Montvale, NJ: Medical Economics Data; 2010.
- Choi JH, Dresler CM, Norton MR, Strahs KR: Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003, 5:635–644. CrossRef
- Shiffman S, Fant RV, Buchhalter AR, et al.: Nicotine delivery systems. Expert Opin Drug Deliv 2005, 2:563–577. CrossRef
- Kaufmann V, Jepson C, Rukstalis M, et al.: Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome. Psychopharmacology (Berl) 2004, 172:271–276. CrossRef
- Tonnesen P, Norregaard J, Mikkelsen K, et al.: A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993, 269:1268–1271. CrossRef
- Mooney ME, Sofuoglu M: Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother 2006, 6:965–981. CrossRef
- Hays JT, Ebbert JO: Bupropion sustained release for treatment of tobacco dependence. Mayo Clin Proc 2003, 78:1020–1024; quiz 1024. CrossRef
- Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007, 1:CD000031.
- Rollema H, Hajos M, Seymour PA, et al.: Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 2009, 78:813–824. CrossRef
- • Sofuoglu M, Herman AI, Mooney M, Waters AJ: Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl) 2009, 207:153–162. Varenicline is a first-line treatment for smoking cessation, but its exact mechanism of action has not been elucidated. This study examined how varenicline affects the physiologic, subjective, and cognitive-enhancing responses to pure nicotine, administered intravenously, in male and female smokers. CrossRef
- Niaura R, Hays JT, Jorenby DE, et al.: The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008, 24:1931–1941. CrossRef
- Prochazka AV, Weaver MJ, Keller RT, et al.: A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998, 158:2035–2039. CrossRef
- Hall SM, Reus VI, Munoz RF, et al.: Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998, 55:683–690. CrossRef
- Frishman WH: Smoking cessation pharmacotherapy. Ther Adv Cardiovasc Dis 2009, 3:287–308. CrossRef
- Gourlay SG, Stead LF, Benowitz NL: Clonidine for smoking cessation. Cochrane Database Syst Rev 2004, 3:CD000058.
- Glassman AH, Covey LS, Dalack GW, et al.: Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993, 54:670–679. CrossRef
- • Piper ME, Smith SS, Schlam TR, et al.: A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009, 66:1253–1262. Few research studies have investigated the relative efficacies of multiple smoking cessation pharmacotherapies. This study compared the efficacy of five smoking cessation pharmacotherapies in a placebo-controlled clinical trial. After correcting for multiple comparisons, the only medication that was more effective than others was the combination of the nicotine patch and nicotine lozenge. CrossRef
- Sweeney CT, Fant RV, Fagerstrom KO, et al.: Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001, 15:453-467. CrossRef
- •• Hall SM, Prochaska JJ: Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol 2009, 5:409–431. In the United States, more than 30% of smokers have psychiatric comorbidity. However, there is limited information to guide clinicians on how best to treat tobacco addiction in this population. The authors reviewed the literature of how best to integrate smoking cessation into mental health and addiction settings. CrossRef
- Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3:A42.
- Tsoh JY, Humfleet GL, Munoz RF, et al.: Development of major depression after treatment for smoking cessation. Am J Psychiatry 2000, 157:368–374. CrossRef
- Prochaska JJ, Hall SM, Tsoh JY, et al.: Treating tobacco dependence in clinically depressed smokers: effect of smoking cessation on mental health functioning. Am J Public Health 2008, 98:446–448. CrossRef
- Evins AE, Cather C, Culhane MA, et al.: A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007, 27:380–386. CrossRef
- George TP, Vessicchio JC, Sacco KA, et al.: A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 2008, 63:1092–1096. CrossRef
- Prochaska JJ, Delucchi K, Hall SM: A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol 2004, 72:1144–1156. CrossRef
- Joseph AM, Willenbring ML, Nugent SM, Nelson DB: A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol 2004, 65:681–691.
- Mooney ME, Poling J, Gonzalez G, et al.: Preliminary study of buprenorphine and bupropion for opioid-dependent smokers. Am J Addict 2008, 17:287–292. CrossRef
- Poling J, Rounsaville BJ, Gonsai K, et al.: The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict 2010 (in press).
- Tong VT, Jones JR, Dietz PM, et al.: Trends in smoking before, during, and after pregnancy—Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 sites, 2000–2005. MMWR Surveill Summ 2009, 58:1–29.
- Colman GJ, Joyce T: Trends in smoking before, during, and after pregnancy in ten states. Am J Prev Med 2003, 24:29–35. CrossRef
- DiFranza JR, Aligne CA, Weitzman M: Prenatal and postnatal environmental tobacco smoke exposure and children’s health. Pediatrics 2004, 113:1007–1015.
- • Oncken CA, Kranzler HR: What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res 2009, 11:1265–1273. This is a comprehensive review of pharmacotherapy for smoking cessation during pregnancy. In the United States, about 13% of women smoke during pregnancy. Smoking during pregnancy is associated with several health risks to the mother and the fetus, emphasizing the need for effective treatments for pregnant women. CrossRef
- Park ER, Chang Y, Quinn V, et al.: The association of depressive, anxiety, and stress symptoms and postpartum relapse to smoking: a longitudinal study. Nicotine Tob Res 2009, 11:707–714. CrossRef
- Marshall L, Schooley M, Ryan H, et al.: Youth tobacco surveillance—United States, 2001–2002. MMWR Surveill Summ 2006, 55:1–56.
- Everett SA, Warren CW, Sharp D, et al.: Initiation of cigarette smoking and subsequent smoking behavior among U.S. high school students. Prev Med 1999, 29:327–333. CrossRef
- Sussman S, Sun P, Dent CW: A meta-analysis of teen cigarette smoking cessation. Health Psychol 2006, 25:549–557. CrossRef
- Lawrence D, Mitrou F, Zubrick SR: Smoking and mental illness: results from population surveys in Australia and the United States. BMC Public Health 2009, 9:285. CrossRef
- Hughes JR: Motivating and helping smokers to stop smoking. J Gen Intern Med 2003, 18:1053–1057. CrossRef
- Comparison of Available Treatments for Tobacco Addiction
Current Psychiatry Reports
Volume 12, Issue 5 , pp 433-440
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Nicotine pharmacotherapy
- Special populations
- Tobacco use disorder
- Clinical trials
- Smoking cessation
- Industry Sectors